Active substance
Trospium
- SFDA 3
- US FDA 14
- Health Canada 1
- US price lines 2
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SPASMEX 30MG FILM COATED TABLET | 30 mg | Film-coated tablet · Oral use | 50 Blister | SAR 115.65 | NCE · Prescription | Dr. Pfleger Arzneimittel GmbH | Valid |
| SPASMOLYT 20 MG COATED TABLETS | 20 mg | Coated tablet · Oral use | 30 Blister | SAR 22.05 | NCE · Prescription | Viatris Healthcare GmbH | Valid |
| SPASMOLYT 20 MG COATED TABLETS | 20 mg | Coated tablet · Oral use | 30 Blister | SAR 63.90 | NCE · Prescription | Rottapharm|Madaus Group | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BENIGN PROSTATIC HYPERTROPHY; URINARY INCONTINENCE AND OVERACTIVE BLADDER
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TROSPIUM CHLORIDE | 20MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 13 Aug 2010 |
| TROSPIUM CHLORIDE | 20MG | tablet · oral | PADAGIS US | Prescription | 17 Nov 2010 |
| TROSPIUM CHLORIDE | 20MG | tablet · oral | APOTEX | Prescription | 6 Dec 2011 |
| TROSPIUM CHLORIDE | 60MG | capsule, extended release · oral | ACTAVIS LABS FL INC | Prescription | 12 Oct 2012 |
| TROSPIUM CHLORIDE | 60MG | capsule, extended release · oral | PADAGIS US | Prescription | 24 May 2013 |
| TROSPIUM CHLORIDE | 20MG | tablet · oral | INVAGEN PHARMS | Prescription | 23 Aug 2016 |
| TROSPIUM CHLORIDE | 20MG | tablet · oral | HERITAGE PHARMS INC | Prescription | 30 Aug 2016 |
| TROSPIUM CHLORIDE | 60MG | capsule, extended release · oral | GRANULES | Prescription | 23 Apr 2020 |
| TROSPIUM CHLORIDE | 60MG | capsule, extended release · oral | UTOPIC PHARMS | Prescription | 30 Apr 2021 |
| TROSPIUM CHLORIDE | 20MG | tablet · oral | CHARTWELL RX | Prescription | 16 Feb 2022 |
| TROSPIUM CHLORIDE | 20MG | tablet · oral | MACLEODS PHARMS | Prescription | 18 Jun 2024 |
| SANCTURA | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ALLERGAN | Discontinued | 28 May 2004 |
| SANCTURA XR | 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | capsule, extended release · oral | ALLERGAN | Discontinued | 3 Aug 2007 |
| TROSPIUM CHLORIDE | 60MG | capsule, extended release · oral | UPSHER SMITH LABS | Discontinued | 29 Apr 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MAR-TROSPIUM | 02488353 | 20 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TROSPIUM CHLORIDE 20 MG TABLET | $0.21142 | per EA | 23 Sep 2026 |
| US NADAC | TROSPIUM CHLORIDE ER 60 MG CAP | $1.64301 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Trospium chloride 20mg tablets | £19.82 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Trospium chloride 60mg modified-release capsules | £23.05 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.